The market did not reward saving the lives of children in poor countries from preventable diseases, and governments did not subsidize it.
Unresolvable The public record could not settle it.
Factual: Statements about the present or the past, checked against the record: did they hold up?
The second judge would not resolve this claim; the verdict shown is the first judge's.
What would count as true or false
The claim has two parts, judged for the period Gates was describing (roughly the 1990s up to 2007): (a) markets gave no meaningful commercial reward for developing or delivering interventions against preventable child deaths in poor countries; (b) governments did not subsidise this work. True: the evidence shows commercial incentives were negligible (e.g. little private R&D or investment aimed at diseases of poor-country children) and government funding (domestic and donor aid) for these interventions was negligible. Mostly true: (a) holds, and government funding existed only at token levels, so 'did not subsidize' is a minor overstatement. Mixed: one part holds and the other is clearly wrong. Mostly false: (a) holds but governments materially funded child-survival work (e.g. substantial donor aid for immunisation or child-health programmes, national immunisation programmes), so (b) is an overstatement of underfunding. False: both parts are contradicted, i.e. there were real market rewards and substantial government subsidies.
Set before the research began.
Evidence (4)
-
E1 Neglected Disease Research and Development: How Much Are We Really Spending? PLoS Medicine (via PubMed Central), authored by Mary Moran and colleagues at the George Institute for International Health · 3 February 2009 Own record
“Neglected disease funding remains primarily the realm of public and philanthropic donors, who collectively invested US$2.3 billion or 90% of the total funding in 2007 (Figure 5).”
-
E2 Neglected Disease Research and Development: How Much Are We Really Spending? PLoS Medicine (via PubMed Central), authored by Mary Moran and colleagues at the George Institute for International Health · 3 February 2009 Own record
“Public donors, including government and multilateral groups, provided US$1.78 billion (69%) while philanthropic and not-for-profit funders invested US$538 million (21%).”
-
E3 Neglected Disease Research and Development: How Much Are We Really Spending? PLoS Medicine (via PubMed Central), authored by Mary Moran and colleagues at the George Institute for International Health · 3 February 2009 Own record
“Other equally high-burden diseases as measured by DALYs (disability-adjusted life years), such as pneumonia and the diarrhoeal illnesses, collectively received less than 6% of total funding.”
-
E4 Neglected Disease Research and Development: How Much Are We Really Spending? PLoS Medicine (via PubMed Central), authored by Mary Moran and colleagues at the George Institute for International Health · 3 February 2009 Own record
“It is also remarkable that investment by some private firms is now rivalling or exceeding spending by many public organisations, and indeed many G7 and OECD countries.”
Reasoning
The evidence shows that public donors, including governments and multilateral groups, provided US$1.78 billion for neglected-disease R&D in 2007 [E1][E2]. It does not show how much of that went to child-survival interventions, and it does not cover donor aid for delivery or national immunisation programmes across the period described. Because of this, and because E4 reports substantial private investment, the evidence does not settle either part of the claim under the criteria.
Cite this claim
Bill Gates, “The market did not reward saving the lives of children in poor countries from preventable diseases, and governments did not subsidize it.” (said 7 June 2007). Verdict: unresolvable. Reliability API, claim c_a46830de2386, method 0.1.0+c876030c, dataset release v1.1.2. https://epistacklabs.com/claims/c_a46830de2386
This claim is in dataset release v1.1.2, with the same verdict.
Reply to this claim
More factual claims by Bill Gates
-
Resolved true
“It has also succeeded in bringing more vaccines and supplies into the market while lowering prices.”
Gavi has brought more vaccines and supplies into the market while lowering prices.
-
Mixed
“If the regulations limit digital banking, as is still the case in most countries, innovators can’t enter.”
Regulations in most countries still limit digital banking, preventing innovators from entering.
-
Mixed
“Traditional banks cannot afford to serve the poor because of their costs.”
Traditional banks cannot afford to serve the poor because of their costs.
-
Mostly true
“Indeed, small loans have helped millions of people, but loans are only one of the financial services the poor need, interest rates are relatively high, and these services have reached only a small…”
-
Resolved true
“For under a dollar, there were interventions that could save lives that just weren’t being delivered.”
Interventions costing under a dollar could save lives but were not being delivered.
Verdicts are made automatically; how verdicts are made.